CD30 has been implicated as an excellent potential target for the treatment of HL and ALCL with the data presented previously (Fanale et al., 2012; Francisco et al., 2003; Gopal et al., 2015; Pro et al., 2012). This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.